[chlororuthenium(II) bis(triphenylphosphane)(η6-p-cymene)] hexafluorophosphate | 846550-68-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: [chlororuthenium(II) bis(triphenylphosphane)(η6-p-cymene)] hexafluorophosphate
• 英文别名: [(η(6)-p-cymene)Ru(PPh3)2Cl]PF6；[(η⁶-p-cymene)RuCl-(imidazole-CO₂H)(PPh₃)]PF₆；[(η⁶-p-cym)RuCl-(imidazole-CO₂H)(PPh₃)]PF₆；[Ru^IICl(p-cymene)(PPh₃)₂][PF₆]；[RuCl(PPh3)2(η6-p-cymene)]PF6
• CAS: 846550-68-3
• 化学式: C₄₆H₄₄ClP₂Ru*F₆P
• 分子量: 940.29
• InChiKey: KPGJFAAFKAGSFC-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  13.6
• 重原子数：
  57
• 可旋转键数：
  7
• 环数：
  7.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  [chlororuthenium(II) bis(triphenylphosphane)(η6-p-cymene)] hexafluorophosphate 在 三乙胺 、 lithium chloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.0h， 生成 [dichloro(p-cymene)(triphenylphosphane)ruthenium(II)]
  参考文献：
  名称：

  Somatostatin Subtype-2 Receptor-Targeted Metal-Based Anticancer Complexes

  摘要：

  Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(eta(6)-bip)Os(4-CO2-pico)Cl] (bip = biphenyl, pico = picolinate) (4), [(eta(6)-p-cym)RuCl](dap)(+) (p-cym = p-cymene) (5), and [(eta(6)-p-cym)RuCl(imidazole-CO2H)(PPh3)](+) (6), were synthesized by using a solid-phase approach. Conjugates 3-5 readily underwent hydrolysis and DNA binding, whereas conjugate 6 was inert to ligand substitution. NMR spectroscopy and molecular dynamics calculations showed that conjugate formation does not perturb the overall peptide structure. Only 6 exhibited antiproliferative activity in human tumor cells (IC50 = 63 +/- 2 mu M in MCF-7 cells and IC50 = 26 +/- 3 mu M in DU-145 cells) with active participation of somatostatin receptors in cellular uptake. Similar cytotoxic activity was found in a normal cell line (IC50 = 45 +/- 2.6 mu M in CHO cells), which can be attributed to a similar level of expression of somatostatin subtype-2 receptor. These studies provide new insights into the effect of receptor-binding peptide conjugation on the activity of metal-based anticancer drugs, and demonstrate the potential of such hybrid compounds to target tumor cells specifically.

  DOI：

  10.1021/bc300173h
• 作为产物：
  描述：

  [RuCl(P(p-C6H4Me)3)(PPh3)(η6-p-cymene)]PF6 以 四氢呋喃 为溶剂， 生成 [chlororuthenium(II) bis(triphenylphosphane)(η6-p-cymene)] hexafluorophosphate 、 [RuCl(P(p-tolyl)3)2(η6-p-cymene)]PF6
  参考文献：
  名称：

  双膦钌（II）-芳烃化合物的催化活性：结构活性相关性

  摘要：

  的范围内的解离膦特征双-膦钌（II）配合物-arene，的[Ru（PPH 3）（PR 3）（η 6 -arene）] PF 6（芳烃= p -cymene：PR 3 = PPhMe 2，PPh 3，P（p- tol）3，PPh 2 i; 芳烃=的PhMe：PR 3 = PPhMe 2，PPH 3），的[Ru（PPH 3）（η 2 -PPh 2（C 6 H ^ 4 O））（η 6 - p -cymene）] PF 6，和将[RuCl（ PPH 3）（η 7 -PPh 2（CH 2）3的pH）] PF 6，已经通过配体交换动力学的组合研究（以P（p -tol）3在THF中）和串联电喷雾电离质谱（ESI-MS / MS）。通过这些研究确定的反应性趋势在芳烃或膦的空间体积，以及膦配体的构象自由度方面得到了合理化。在这些趋势之间，尤其是从ESI-MS / MS数据，与作为苯乙烯加氢成乙苯（在THF中

  DOI：

  10.1021/om070050d

文献信息

• Influence of PPh3 moiety in the anticancer activity of new organometallic ruthenium complexes
  作者：Rubén Sáez、Julia Lorenzo、Ma Jose Prieto、Mercè Font-Bardia、Teresa Calvet、Nuria Omeñaca、Marta Vilaseca、Virtudes Moreno

  DOI：10.1016/j.jinorgbio.2014.03.002

  日期：2014.7

  The effect of the PPh3 group in the antitumor activity of some new organometallic ruthenium(II) complexes has been investigated. Several complexes of the type [Ru((II))(Cl)(PPh3)(Lig-N)], [Ru((II))(Cl)2(Lig-N)] (where Lig-N=pyridine derivate) and [Ru((II))(Cl)(PPh3)2], have been synthesized and characterized. A noticeable increment of the antitumor activity and cytotoxicity of the complexes due to the presence of PPh3 moiety has also been demonstrated, affording IC50 values of 5.2 μM in HL-60 tumor cell lines. Atomic force microscopy, circular dichroism and electrophoresis experiments have proved that these complexes can bind DNA resulting in a distortion of both secondary and tertiary structures. Ethidium bromide displacement fluorescence spectroscopy studies and viscosity measurements support that the presence of PPh3 group induces intercalation interactions with DNA. Indeed, crystallographic analysis, suggest that intra-molecular π-π interactions could be involved in the intercalation within DNA base pairs. Furthermore, high performance liquid chromatography mass spectrometry (HPLC-MS) studies have confirmed a strong interaction between ruthenium complexes and proteins (ubiquitin and potato carboxypeptidase inhibitor - PCI) including slower kinetics due to the presence of PPh3 moiety, which could have an important role in detoxification mechanism and others. Finally, ion mobility mass spectrometry (IMMS) experiments have proved that there is no significant change in the gas phase structural conformation of the proteins owing to their bonding to ruthenium complexes.